RxDoctor Payments Data

William Sauer, MD

Cardiovascular Disease · Aurora, CONPI 1609827583

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Biosense Webster, Inc. at 40.6% of the total. 2025 is the largest year on record at $99,765, 2.6 times the $38,384 reported in 2019. Among cardiovascular disease clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$365,129in general payments, 2019–2025

Across 477 payments — averaging $765.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$148K
  • Abbott$84K
  • Biotronik Inc.$66K
  • Boston Scientific$38K
  • Medical Device Business Services, Inc.$28K
  • Siemens Medical Solutions USA, Inc.$1K
  • plus $713 from 5 others
$612,625in research payments, 2019–2025

Across 40 payments — averaging $15,316 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biosense Webster, Inc.$467K
  • Medtronic$123K
  • Boston Scientific$22K

What the payments were for

  • Consulting fees$183,10850%
  • Speaking & faculty fees$112,02831%
  • Travel & lodging$48,67713%
  • Food & beverage$21,3166%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$365,129 in reported general payments places this provider in the 95th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$186,741
Medicare patients
1,370
Services billed
2,634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Flecainide Acetate13$1,174
Metoprolol Succinate13$286

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →